optimark (gadoversetamide) injection, solution
For Intravenous Injection Only
|PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION|
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration (See WARNINGS).
OptiMARK® (gadoversetamide injection) is a formulation of a nonionic gadolinium chelate of diethylenetriamine pentaacetic acid bismethoxyethylamide (gadoversetamide), for use in magnetic resonance imaging (MRI). OptiMARK® Injection is to be administered by intravenous injection only.
OptiMARK® Injection is provided as a sterile, nonpyrogenic, clear, colorless to pale yellow, aqueous solution of gadoversetamide. No preservative is added. Each mL of OptiMARK® Injection contains 330.9 mg of gadoversetamide (0.5 millimole), 28.4 mg of calcium versetamide sodium (0.05 millimole), 0.7 mg calcium chloride dihydrate (0.005 millimole), and water for injection. Sodium hydroxide and/or hydrochloric acid may have been added for pH adjustment.
OptiMARK® Injection is designated chemically as [8, 11-bis(carboxymethyl)-14-[2-[(2-methoxyethyl)amino]-2-oxoethyl]-6-oxo-2-oxa-5,8,11,14-tetraazahexadecan-16-oato(3-)] gadolinium with a formula weight of 661.77 g/mol and empirical formula of C20H34N5O10Gd. The structural formula of gadoversetamide in aqueous solution is:
OptiMARK® Injection has a pH of 5.5 to 7.5 and pertinent physiochemical data are provided below:
|Osmolality (mOsmol/kg water) @ 37°C||1110|
|Density (g/mL) @ 25°C||1.160|
OptiMARK® Injection has an osmolality of approximately 3.9 times that of plasma (285 mOsm/kg water) and is hypertonic under conditions of use.
OptiMARK® Injection contains gadoversetamide, a complex formed between a chelating agent (versetamide) and a paramagnetic ion, gadolinium (III). Gadoversetamide is a paramagnetic agent that develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment can enhance the relaxation rates of water protons in its vicinity, leading to an increase in signal intensity (brightness) of tissues.
The pharmacokinetics of intravenously administered gadoversetamide in normal subjects conforms to a two-compartment open-model with mean distribution and elimination half-lives (reported as mean ± SD) of about 13.3 ± 6.8 and 103.6 ± 19.5 minutes.
Gadoversetamide does not undergo protein binding in vitro. In pregnant and lactating rats which received 153Gd-labeled gadoversetamide, radioactivity was detected in the placenta, fetus, and maternal milk. (See PRECAUTIONS, Pregnancy Category C and Nursing Mothers.) The volume of distribution at steady state of gadoversetamide in normal subjects is 162 ± 25 mL/kg, roughly equivalent to that of extracellular water. (See PRECAUTIONS, Pregnancy Category C.)
Biotransformation or decomposition of gadoversetamide was not detected.
Gadoversetamide (0.1 mmol/kg) is eliminated primarily in the urine with 95.5 ± 17.4% (mean ± SD) of the administered dose eliminated by 24 hours. Animal data demonstrated that insignificant levels of radioactive [153Gd] MP-1177/10 are eliminated via the feces. In experimentally induced anephria in the rat, hepatobiliary excretion did not significantly compensate for the absence of urinary elimination. The renal and plasma clearance rates of gadoversetamide in normal subjects are essentially identical (69 ± 15.4 and 72 ± 16.3 mL/hr/kg, respectively) indicating that the drug is essentially cleared through the kidneys via glomerular filtration. Within the studied dose range (0.1 to 0.7 mmol/kg), the kinetics of gadoversetamide appear to be linear. (See PRECAUTIONS.)
Renal Insufficiency: A single intravenous dose of 0.1 mmol/kg of OptiMARK® Injection was administered to 28 (17 men and 11 women) patients with impaired renal function (mean serum creatinine of 2.4 mg/dL). Sixteen patients had concurrent central nervous system or liver pathology. Renal impairment was shown to delay the elimination of gadoversetamide (see Table 2). The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function. (See CLINICAL PHARMACOLOGY, Elimination and Hemodialysis.)
Hemodialysis: Gadoversetamide is removed from the body by hemodialysis. Approximately 98% of the administered dose (0.1 mmol/kg) was cleared from the circulation over the three dialysis sessions that occurred 2 hours, 48 hours, and 120 hours after injection. After each of three dialysis sessions, respectively, 70%, 93%, and 98% of the administered dose was cleared from the plasma. The mean dialysis clearance of gadoversetamide was 93.2 ± 17.1 mL/min, or 48% of the creatinine clearance (194 ± 18.6 mL/min), using a high flux PMMA membrane. (See CLINICAL PHARMACOLOGY, Special Populations and Elimination, PRECAUTIONS.)
Hepatic Insufficiency: A single intravenous dose of 0.1 mmol/kg of OptiMARK® Injection was administered to 4 (2 men and 2 women) patients with impaired hepatic function. Hepatically impaired patients with normal renal function had plasma kinetics similar to normal subjects. (See Table 2.)
Gender differences were not statistically significant within the hepatically impaired or renally impaired subgroups. (See Table 2.)
|Population||Elimination t 1/2 (hours)|
|Men (N = 52)||Women (N = 48)|
|Healthy Volunteers||1.73 ± 0.31 (N = 8)||1.73 ± 0.40 (N = 4)|
|Normal Patients||1.90 ± 0.50 (N = 25)||1.94 ± 0.57 (N = 31)|
|Renally Impaired||8.74 ± 5.14 (N = 17)||6.91 ± 2.46 (N = 11)|
|Hepatically Impaired||2.09 ± 0.03 (N = 2)||2.35 ± 1.09 (N = 2)|
Pharmacokinetic parameters were retrospectively evaluated in 121 patients with a mean age of 46 years (range 18 to 76 years). In these patients, age related effects on pharmacokinetic parameters were not observed.
Pharmacokinetic differences due to race after intravenous OptiMARK® Injection were not studied.
Drug interactions have not been studied.
Dietary effects on the pharmacokinetics of OptiMARK® Injection have not been studied.
In magnetic resonance imaging (MRI), visualization of normal and pathological brain, spinal and hepatic tissue depends in part on variations in the radiofrequency signal intensity that occurs with: 1) changes in proton density; 2) alterations of the spin-lattice or longitudinal relaxation time (T1); and 3) variation of the spin-spin or transverse relaxation time (T2). When placed in a magnetic field, gadoversetamide decreases T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity (brightness).
OptiMARK® Injection does not cross the intact blood brain barrier, and, therefore, does not accumulate in the normal brain or in lesions that may have a normal blood-brain barrier (e.g., cysts, mature post-operative scars, etc.). However, disruption of the blood-brain barrier or abnormal vascularity allows accumulation of OptiMARK® Injection in the extravascular spaces of lesions such as neoplasms, abscesses, and subacute infarcts. The pharmacokinetic parameters of OptiMARK® Injection in various lesions are not known.
A total of 790 patients were evaluated in 4 controlled clinical trials (two liver and two central nervous system studies) of OptiMARK® Injection. Of these 790 patients, 461 received OptiMARK® Injection. Of the 461 OptiMARK® patients, there were 252 men and 209 women with a mean age of 49 years (range 12 to 82 years). The racial and ethnic representations were 83% Caucasian, 9% Black, 3% Asian, and 5% other racial or ethnic groups. These trials were designed to evaluate the results of combined non-contrast MRI and OptiMARK® Injection 0.1 mmol/kg contrast MRIs in comparison to non-contrast MRI alone.
In the two controlled central nervous system (CNS) studies, 395 eligible patients were highly suspect for CNS disorders and had an abnormal entry contrast MRI. After enrollment, patients were randomized to receive repeat MRI evaluations with OptiMARK® Injection 0.1 mmol/kg or with 0.1 mmol/kg of an approved gadolinium contrast agent. Of these 395 patients, 262 received OptiMARK® Injection and 133 received the approved gadolinium contrast agent. The studies were not prospectively designed to demonstrate superiority or equivalence of either imaging drug. Approximately 40% and 25% of the patients that were enrolled in Study A and B, respectively, had a history of either surgery, biopsy, and/or radiation, and/or chemotherapy.
Pre-contrast and pre-plus-post-contrast images were independently evaluated by three blinded readers (each reader examined approximately 1/3 of the images). The images were evaluated by the blinded readers for the following endpoints using a scale from 1 to 10: the level of conspicuity of all lesions, the ability to delineate lesion borders from parenchyma/structures, the number of lesions, and the confidence in the number of lesions. As shown in Table 3, the first row of each endpoint group represents the difference in the mean score of the combined pre- and post-contrast MRI from the mean score of the pre-contrast MRI alone. Also, the table shows the number of patients whose paired MRI images were better, worse or the same as the pre-contrast MRI. Results from the contrast image alone were not evaluated. In Table 3 for these endpoints, when read in combination with the noncontrast images, OptiMARK® Injection provided a statistically significant improvement over baseline. In addition to these measures, the images were evaluated for the blinded reader's confidence in the diagnosis. Although improvement over baseline was noted, the diagnosis was not rigorously confirmed.
(a) Difference of means = (Side-by-side pre and post OptiMARK® mean) - (pre mean)
(b) Pair = Side-by-side pre and post OptiMARK®
* Statistically significant for both the median (Wilcoxon test) and mean (paired t test)
◊ Statistically significant for median (Wilcoxon test)
† 1 patient was excluded from this analysis because a non-contrast image was not obtained for that patient
|Study A||Study B|
N = 132 †
N = 129
|Difference of Means (a)||0.39*||0.66*|
|Worse||24 (18%)||24 (19%)|
|Same||69 (52%)||52 (40%)|
|Better||39 (30%)||53 (41%)|
|Difference of Means||0.70*||0.86*|
|Worse||23 (17%)||25 (19%)|
|Same||55 (42%)||51 (40%)|
|Better||54 (41%)||53 (41%)|
|Number of Lesions:|
|Difference of Means|
|Worse||9 (7%)||16 (12%)|
|Same||101 (77%)||86 (67%)|
|Better||22 (16%)||27 (21%)|
|Confidence in Number of Lesions:|
|Difference of Means||0.11*||0.56*|
|Worse||19 (14%)||18 (14%)|
|Same||86 (65%)||60 (47%)|
|Better||27 (20%)||51 (40%)|
In the two controlled liver studies of 395 patients, all eligible patients had a contrast CT that was considered highly suspect for a liver abnormality(ies). Of these 395 patients, 199 received OptiMARK® Injection 0.1 mmol/kg. Patients had both pre-contrast and post-contrast MRI scans covering the entire liver. In each study, the images were read by 3 blinded readers (each reader examined approximately 1/3 of the images). Using a scale of 1 to 10, the images were evaluated by the blinded readers for the level of conspicuity of all lesions, the ability to delineate lesion borders from parenchyma/structures, the number of lesions and confidence in the number of lesions. The results are shown in Table 4.
The first row of each endpoint group represents the difference in the mean score of the combined pre- and post-contrast MRI from the mean score of the pre-contrast MRI alone. Also, the table shows the number of patients whose paired MRI images were better, worse or the same as the pre-contrast MRI. Results from the contrast image alone were not evaluated. As shown in Table 4 for these endpoints, when read in combination with the noncontrast image, OptiMARK® Injection provided a statistically significant improvement over noncontrast images. In addition to these measures, the images were evaluated for the blinded reader's confidence in the diagnosis. Although improvement over baseline was noted, the trial was not designed to rigorously confirm the diagnosis.
(a) Difference of means = (Side-by-side pre and post OptiMARK® mean) - (pre mean)
(b) Pair = Side-by-side pre and post OptiMARK®
* Statistically significant for both the median (Wilcoxon test) and mean (paired t test)
† Borderline statistical significance in paired t test
|Study C||Study D|
N = 99
N = 100
|Difference of Means (a)||0.77*||0.75*|
|Worse||21 (21%)||14 (14%)|
|Same||37 (37%)||50 (50%)|
|Better||41 (41%)||36 (36%)|
|Difference of Means||0.77*||0.69*|
|Worse||21 (21%)||15 (15%)|
|Same||38 (38%)||45 (45%)|
|Better||40 (40%)||40 (40%)|
|Number of Lesions:|
|Difference of Means|
|Worse||13 (13%)||16 (16%)|
|Same||50 (51%)||58 (58%)|
|Better||36 (36%)||26 (26%)|
|Confidence in Number of Lesions:|
|Difference of Means||1.6*||1.0*|
|Worse||39 (39%)||38 (38%)|
|Same||2 (2%)||8 (8%)|
|Better||58 (59%)||54 (54%)|
A subsequent study of 140 normal volunteers evaluated the safety of OptiMARK® Injection 0.1 mmol/kg delivered by power injector. Imaging results were not studied. The normal volunteers were randomized to receive OptiMARK® injected manually, or OptiMARK® or saline injected at 3 different power injector rates. At 2 mL/sec, the adverse event rates were comparable in the OptiMARK® and saline controls when delivered manually and by power injector. In these small sample sizes, there was a trend towards increasing adverse events with increasing rates of power injection. Patients with abnormal vascularity were not evaluated. The safety and efficacy of power injector rates higher than 2 mL/sec has not been established.
OptiMARK® Injection is indicated for use with magnetic resonance imaging (MRI) in patients with abnormal blood brain barrier or abnormal vascularity of the brain, spine and associated tissues.
OptiMARK® Injection is indicated for use with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities on computed tomography.
OptiMARK® Injection is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium, versetamide, or any of the inert ingredients.
Deoxygenated sickle erythrocytes have been shown in vitro studies to align perpendicular to a magnetic field; this may result in vaso-occlusive complications in vivo. The enhancement of magnetic moment by gadoversetamide may potentiate sickle erythrocyte alignment. OptiMARK® Injection in patients with sickle cell anemia and other hemoglobinopathies has not been studied.
The potential risk of hemolysis after injection of OptiMARK® Injection in patients with other hemolytic anemias has not been studied.
Patients with history of allergy, renal insufficiency or drug reaction should be observed for several hours after drug administration. (See PRECAUTIONS.)
Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2) and in patients with acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced MRI. For patients receiving hemodialysis, physicians may consider the prompt initiation of hemodialysis following the administration of a gadolinium-based contrast agent in order to enhance the contrast agent's elimination. The usefulness of hemodialysis in the prevention of NSF is unknown.
Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a gadolinium-based contrast agent and the degree of renal function impairment at the time of exposure.
Post-marketing reports have identified the development of NSF following single and multiple administrations of gadolinium-based contrast agents. These reports have not always identified a specific agent. Where a specific agent was identified, the most commonly reported agent was gadodiamide (OmniscanTM), followed by gadopentetate dimeglumine (Magnevist®) and gadoversetamide (OptiMARK®). NSF has also developed following sequential administrations of gadodiamide with gadobenate dimeglumine (MultiHance®) or gadoteridol (ProHance®). The number of post-marketing reports is subject to change over time and may not reflect the true proportion of cases associated with any specific gadolinium-based contrast agent.
The extent of risk for NSF following exposure to any specific gadolinium-based contrast agent is unknown and may vary among the agents. Published reports are limited and predominantly estimate NSF risks with gadodiamide. In one retrospective study of 370 patients with severe renal insufficiency who received gadodiamide, the estimated risk for the development of NSF was 4% (J Am Soc Nephrol 2006;17:2359). The risk, if any, for the development of NSF among patients with mild to moderate renal insufficiency or normal renal function is unknown.
Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent prior to any readministration. (See CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
Some paramagnetic contrast agents may impair the visualization of existing lesions, which are seen on the unenhanced, noncontrast MRI. This may be due to effects of the paramagnetic contrast agent, imaging parameters, misregistration, etc. CAUTION SHOULD BE EXERCISED WHEN A CONTRAST ENHANCED INTERPRETATION IS MADE IN THE ABSENCE OF A COMPANION UNENHANCED MRI.
Since gadoversetamide is cleared from the body by glomerular filtration, caution should be exercised in patients with impaired renal function. Dose adjustments in renal impairment have not been studied. Dialysis may be needed to clear OptiMARK® Injection if it is administered to patients with significant renal impairment. OptiMARK® Injection has been shown to be removed from the body by hemodialysis. (See CLINICAL PHARMACOLOGY, ELIMINATION and SPECIAL POPULATIONS, Renal Insufficiency.)
The possibility of a reaction, including serious, life threatening, fatal, anaphylactoid or cardiovascular reactions or other idiosyncratic reactions should always be considered especially in those patients with a known clinical hypersensitivity, a history of asthma, or other respiratory disorders. (See ADVERSE REACTIONS.)
Repeat procedures: The safety of repeated doses has not been studied.
Diagnostic procedures involving the use of MRI contrast agents should be conducted under supervision of a physician with the prerequisite training and a thorough knowledge of the procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast itself.
Patients receiving OptiMARK® Injection should be instructed before injection to:
Drug interactions with other contrast agents and other drugs have not been studied.
Interference by OptiMARK® Injection in the measurement of serum iron, copper and zinc has been observed. OptiMARK® Injection causes interference in the measurement of serum calcium using the ortho-cresophthalin complexone (OCP) colorimetric method. In the presence of OptiMARK® Injection, OCP produces an erroneous, low value for serum calcium. The magnitude of this artifact is proportional to the concentration of OptiMARK® Injection in the blood, and accurate values can be obtained approximately 90 minutes following injection. In patients with renal insufficiency, clearance of OptiMARK® Injection is slowed and the interference with calcium determination by OCP is prolonged. Neither the arsenazo III dye system nor the inductively coupled plasma mass spectroscopy methods for calcium assay are affected by OptiMARK® Injection.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of gadoversetamide. The results of the following genotoxicity assays were negative: Salmonella/E.Coli reverse mutation (Ames) assay, mouse lymphoma mutagenesis assay, and the in vivo mammalian micronucleus assay. The in vitro CHO chromosome aberration assay without metabolic activation was positive.
OptiMARK® Injection administered to rats in a fertility study was shown to have irreversible reduction and degeneration of spermatocytes in testes and epididymides, and impaired male fertility, following intravenous doses of 2.0 mmol/kg/day (4 times the human dose based on body surface area) for 7 weeks. These effects were not observed at 0.5 mmol/kg/day (1 times the human dose based on a body surface area).
In a separate 28-day repeat dose study in rats, OptiMARK® Injection was shown to have irreversible reduction of male reproductive organ weights, degeneration of the germinal epithelium of the testes, presence of germ cells in the epididymides, and reduced sperm count, following daily intravenous doses of 3.0 mmol/kg/day (6 times the human dose based on body surface area). These effects were not observed at 0.6 mmol/kg/day (1 times the human dose based on surface area). These effects were not observed in similar studies conducted in dogs.
In a single dose study in rats, OptiMARK® Injection did not produce adverse effects on the male reproductive system 24 hours and 14 days after intravenous administration of 0.5 to 15 mmol/kg (1 to 25 times the human dose based on body surface area).
OptiMARK® Injection reduced neonatal weights from birth through weaning at maternal doses of 0.5 mmol/kg/day (1 times the human dose based on body surface area) for 5 weeks (including gestation) and paternal doses of 0.5 mmol/kg/day for 12 weeks. This effect was not observed at 0.1 mmol/kg (0.2 times the human dose based on a body surface area). Maternal toxicity was not observed at any dose.
OptiMARK® Injection caused a reduced mean fetal weight, abnormal liver lobation, delayed ossification of sternebrae, and delayed behavioral development (startle reflex and air rights reflex) in fetuses from female rats dosed with 4.9 mmol/kg/day (10 times the human dose based on body surface area) on days 7 through 17 of gestation. These effects were not observed at 0.7 mmol/kg/day (1 times the human dose based on body surface area). Maternal toxicity was observed at 4.9 mmol/kg/day.
OptiMARK® Injection caused forelimb flexures and cardiovascular changes in fetuses from female rabbits dosed with 0.4 and 1.6 mmol/kg/day (respectively, 1 and 4 times the human dose based on body surface area) on gestation days 6 through 18. The cardiovascular changes were malformed thoracic arteries, a septal defect, and abnormal ventricle. These effects were not observed at 0.1 mmol/kg/day (0.3 times the human dose based on body surface area). Maternal toxicity was not observed at any dose.
Adequate and well-controlled studies were not conducted in pregnant women. OptiMARK® Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
153Gd-labeled OptiMARK® Injection was excreted in the milk of lactating rats receiving a single intravenous dose of 0.1 mmol/kg. Women should discontinue nursing and discard breast milk up to 72 hours after OptiMARK® Injection administration. (See CLINICAL PHARMACOLOGY, Distribution.)
Safety and effectiveness of OptiMARK® Injection in pediatric patients have not been established.
A total of 1309 subjects (24 healthy volunteers and 1285 patients) received OptiMARK® Injection and 46 subjects received placebo (saline). Of the 1309 subjects who received OptiMARK® Injection, 680 (52%) were men and 629 (48%) were women with a mean age of 50 years (range 12 to 85 years). In this population there were 1102 (84%) white, 116 (9%) black, 33 (3%) Asian, and 58 (4%) subjects and patients of other racial groups.
In the clinical trials there were 8 serious adverse events and 1 death. The one death occurred in a patient with advanced multisystem disease and appeared to be related to the underlying disease. Six of the eight serious events appeared to be related to underlying disease. Two patients had either persistent paresthesia or numbness of unknown etiology that required hospitalization for diagnostic evaluations or treatment.
Of the 1309 subjects, 460 (35%) reported at least one adverse event out of a total of 997 adverse events; and 22 (47.8%) of the 46 subjects who received placebo reported at least one adverse event out of a total of 81 adverse events.
The most commonly noted adverse events were headache (9.4%), vasodilatation (6.4%), taste perversion (6.2%), dizziness (3.7%), nausea (3.2%), and paresthesia (2.2%). All adverse events reported in 1% or greater of all patients are listed in Table 5. Of the subjects and patients who experienced adverse events, 95.8% of the adverse events were of mild or moderate intensity after dosing with OptiMARK® Injection.
|Body System or Event Type||
OptiMARK® (N = 1309)
|Number of patients with one or
more adverse events
|Total Number of Adverse Events||997|
|Patients with any injection
|Body as a Whole||193 (14.7%)|
|Pain Abdomen||24 (1.8%)|
|Pain Back||16 (1.2%)|
|Injection Site||35 (2.7%)|
|Injection Site Reaction||20 (1.5%)|
|Nervous System||109 (8.3%)|
|Skin and Appendages||37 (2.8%)|
|Special Senses||96 (7.3%)|
|Taste Perversion||81 (6.2%)|
The following adverse reactions occurred in less than 1% of the patients:
Body as a Whole: allergic reaction, edema face, fever, flu-like syndrome, malaise, mucous membrane discharge, neck rigidity, neck pain, pelvic pain, increased sweating
Cardiovascular: arrhythmia, chest pain, hypertension, hypotension, pallor, palpitation, syncope, tachycardia, vasospasm
Digestive: anorexia, increased appetite, constipation, dry mouth, dysphagia, eructation, flatulence, increased salivation, thirst, vomiting
Hemic and Lymphatic: thrombocytopenia
Metabolic and Nutritional: increased creatinine, edema, hypercalcemia, hyperglycemia, hypoglycemia, hyponatremia
Musculoskeletal: arthralgia, leg cramps, myalgia, myasthenia, spasm
Nervous System: agitation, anxiety, confusion, depersonalization, diplopia, dystonia, hallucinations, hypertonia, hypesthesia, nervousness, somnolence, tremor, vertigo
Respiratory System: asthma, cough, dyspnea, epistaxis, hemoptysis, laryngismus, pharyngitis, sinusitis, voice alteration
Skin and Appendages: application site reaction, edema injection site, erythema multiforme, pruritus, rash macular-papular and vesicullous bullous, skin dry, thrombophlebitis, inflammation injection site, urticaria
Special Senses: amblyopia, conjunctivitis, hyperacusis, parosmia, tinnitus
Urogenital: dysuria, oliguria, urine frequency.
Post-marketing surveillance reports have identified cases of seizure.
Clinical consequences of overdosage with OptiMARK® Injection have not been reported. Treatment of an overdose is directed toward the support of all vital functions and prompt institution of symptomatic therapy. OptiMARK® Injection has been shown to be dialyzable. (See CLINICAL PHARMACOLOGY.)
OptiMARK® Injection should be administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual or by power injection.
|Body Weight||0.1 mmol/kg|
|Kilograms (kg)||Pounds (lb)||Volume (mL)|
The imaging procedure should be completed within 1 hour of the injection of OptiMARK® Injection. The safety of repeat doses has not been studied. OptiMARK® MRI images should be interpreted in comparison to unenhanced MRI. (See CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Trials.)
Parenteral products should be inspected visually for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored or particulate matter is present.
Concurrent medications or Parenteral Nutrition should not be physically mixed with contrast agents and should not be administered in the same intravenous line because of the potential for chemical incompatibility.
This product has not been evaluated for use in magnetic resonance angiography.
Pharmacy Bulk Package Preparation: NOT FOR DIRECT INFUSION
The 50 mL Pharmacy Bulk Package is used as a multiple dose container with an appropriate transfer device to fill empty sterile syringes.
OptiMARK® Injection should be drawn into the syringe and administered using sterile technique. If nondisposable equipment is used, scrupulous care should be taken to prevent residual contamination with traces of cleansing agents. To ensure complete injection of the contrast medium the injection should be followed by a 5 mL normal saline flush. Unused portions of the drug must be discarded.
When OptiMARK® Injection is to be injected using plastic disposable syringes, the contrast should be drawn into the syringe and used immediately.
OptiMARK® Injection is a clear, colorless to slightly yellow solution containing 330.9 mg/mL, 0.5 mmol/mL of gadoversetamide. OptiMARK® Injection is supplied in 50 mL glass bottles containing 50 mL of solution. Each bottle is rubber stoppered with an aluminum seal and the contents are sterile. Bottles are contained in shipping cartons with the following configurations:
50 mL in glass vials in cartons of 5 bottles (NDC Code 0019-1177-50)
OptiMARK® Injection should be stored at 20°C to 25°C (68°F to 77°F)[see USP Controlled Room Temperature] and protected from light and freezing. OptiMARK® Injection may be stored at 37°C for up to one month in a contrast media warmer utilizing circulating warm air. For periods longer than one month, store at 20°C to 25°C (68°F to 77°F).
This product is covered by U.S. Patent No. 5130120, 5137711, 5508288. The use of this product is covered by U.S. Patent No. 5130120 and 5137711.
OptiMARK is a registered trademark of Mallinckrodt Inc.
Omniscan is a registered trademark of GE Healthcare AS
Magnevist is a registered trademark of Berlex Laboratories, Inc.
MultiHance is a registered trademark of Bracco International B.V.
ProHance is a registered trademark of Bracco Diagnostics Inc.
Copyright 1998, Mallinckrodt Inc.
All rights reserved
Manufactured and Distributed by:
St. Louis, MO 63042 USA
Printed in U.S.A.
Printed in U.S.A.
Data are from FDA and U.S. National Library of Medicine.